摘要
目的分析卡瑞利珠单抗+化疗对晚期非小细胞肺癌的疗效,同时探究这一联合用药方案对肿瘤标志物的影响。方法将2022年3月至2023年10月晚期非小细胞肺癌患者(68例)设置为研究样本,根据患者应用免疫药物的意愿,将不接受应用免疫药物的34例患者纳入对照组,给与含铂双药化疗,接受免疫治疗的34例患者纳入研究组,在常规化疗方案实施基础上联合应用卡瑞利珠单抗。对比两组治疗有效率,治疗前后肿瘤标志物水平[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、糖类抗原50(CA50)]、免疫指标水平[免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)]及不良反应发生情况。结果研究组治疗有效率(82.35%)高于对照组(58.82%),差异具有统计学意义(P<0.05);治疗前两组CEA、CYFRA21-1、CA50测值对比差异无统计学意义(P>0.05),治疗后两组CEA、CYFRA21-1、CA50测值均低于治疗前,且研究组测值低于对照组,差异均有统计学意义(P<0.05);治疗前两组IgA、IgG、IgM测值对比差异无统计学意义(P>0.05),治疗后两组IgA、IgG、IgM测值均高于治疗前,且研究组测值高于对照组,差异均有统计学意义(P<0.05);研究组用药治疗期间不良反应发生率(20.59%)与对照组(14.71%)比较,差异无统计学意义(P>0.05)。结论晚期非小细胞肺癌行卡瑞利珠单抗+化疗治疗可取得较理想的疗效,与临床常规治疗方案对比,该联合治疗方案治疗后肿瘤标志物水平更低,免疫功能恢复更理想,且安全性具有保障,值得应用。
Objective To analyze the therapeutic effect of combination therapy with Camrelizumab and chemotherapy on advanced non-small-cell lung cancer,and to explore the impact of this combination therapy on tumor markers.Methods A total of 68 patients with advanced non-small-cell lung cancer from March 2022 to October 2023 were selected as study samples.According to the willingness of patients to receive immunotherapy,34 patients who did not accept immunotherapy were included in the control group.Cisplatin and carboplatin chemotherapy was given,and 34 patients who received immunotherapy were included in the study group,Camrelizumab was used in combination with conventional chemotherapy.The effective rate of the two groups was compared,the levels of tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 50(CA50)],immune indicators[immunoglobulin A(IgA),immunoglobulin G(IgG), immunoglobulin M (IgM)], and the occurrence of adverse reactions were compared before and after treatment. Results The effective rate of treatment in the study group (82.35%) was higher than that in the control group (58.82%), and the difference was statistically significant (P < 0.05);There was no statistically significant difference in the CEA, CYFRA21-1, and CA50 values between the two groups before treatment (P > 0.05). After treatment, the CEA, CYFRA21-1, and CA50 values in both groups were lower than those before treatment, and the study group was lower than the control group, with statistical significance (P < 0.05);There was no statistically significant difference in the IgA, IgG, and IgM values between the two groups before treatment (P > 0.05). After treatment, the IgA, IgG, and IgM values in both groups were higher than those before treatment, and the study group had higher values than the control group, with statistical significance (P < 0.05);The incidence of adverse reactions during medication treatment in the study group (20.59%) was not statistically significant compared to the control group
作者
胡少博
HU Shaobo(Department of Respiratory and Critical Care Medicine,Luoyang Central Hospital,Luoyang Henan 471000,China)
出处
《临床研究》
2024年第6期89-92,共4页
Clinical Research
